Russia has expressed its readiness to transfer technologies for the production of the Sputnik V coronavirus vaccine to Ukraine. Kirill Dmitriev, the head of the Russian Direct Investment Fund (RDIF), announced this.
According to him, RDIF is ready to fully transfer all the technologies associated with the production of funds. Dmitriev noted that Russia also agrees to begin clinical trials of the joint vaccine AstraZeneca and Sputnik in Ukraine. He stressed that the issue of vaccines should be outside of politics.
As we reported earlier, Russia's Sputnik V coronavirus vaccine has showed 91.4 efficacy, according to data analysis of the final control point of clinical trials.
"Calculation was based on the analysis of data of volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol,"Russian Direct Investment Fund (RDIF) informed.
Meanwhile, the vaccine demonstrated 100 % efficacy against severe coronavirus cases. There were 20 severe cases of coronavirus infection among confirmed cases in the placebo group and no severe cases in the vaccine group.